Clinical Association between Gout and Parkinson's Disease: A Nationwide Population-Based Cohort Study in Korea

被引:9
作者
Kim, Ji Hyoun [1 ]
Choi, In Ah [1 ,2 ]
Kim, Aryun [3 ]
Kang, Gilwon [4 ]
机构
[1] Chungbuk Natl Univ Hosp, Div Rheumatol, Dept Internal Med, Cheongju 28644, South Korea
[2] Chungbuk Natl Univ, Dept Internal Med, Coll Med, Cheongju 28644, South Korea
[3] Chungbuk Natl Univ Hosp, Dept Neurol, Cheongju 28644, South Korea
[4] Chungbuk Natl Univ, Dept Hlth Informat & Management, Coll Med, Cheongju 28644, South Korea
来源
MEDICINA-LITHUANIA | 2021年 / 57卷 / 12期
关键词
gout; uric acid; Parkinson's disease; INCREASES DOPAMINE RELEASE; URIC-ACID LEVELS; OXIDATIVE STRESS; STATIN USE; EPIDEMIOLOGY; ANTIOXIDANT; CHOLESTEROL; PREVALENCE; RISK; MORPHINE;
D O I
10.3390/medicina57121292
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives: This retrospective cohort study aimed to investigate the association between gout and Parkinson's disease (PD) in Korea. Materials and Methods: Overall, 327,160 patients with gout and 327,160 age- and sex-matched controls were selected from the Korean National Health Insurance Service (NHIS) database. PD incidence was evaluated by reviewing NHIS records during the period from 2002 to 2019. Patients with a diagnosis of gout (International Classification of Diseases-10 (ICD-10), M10) who were prescribed medications for gout, including colchicine, allopurinol, febuxostat, and benzbromarone for at least 90 days were selected. Patients with PD who were assigned a diagnosis code (ICD-G20) and were registered in the rare incurable diseases (RID) system were extracted. Results: During follow-up, 912 patients with gout and 929 control participants developed PD. The incidence rate (IR) of overall PD (per 1000 person-years) was not significantly different between both groups (0.35 vs. 0.36 in gout and control groups, respectively). The incidence rate ratio (IRR) was 0.98 (95% CI: 0.89-1.07). The cumulative incidence of PD was not significantly different between the groups. No association between gout and PD was identified in univariate analysis (HR = 1.00, 95% CI: 0.91-1.10, p = 0.935). HR increased significantly with old age (HR = 92.08, 198, and 235.2 for 60-69 years, 70-79 years, and over 80 years, respectively), female sex (HR = 1.21, 95% CI: 1.07-1.37, p = 0.002), stroke (HR = 1.95, 95% CI: 1.76-2.16, p < 0.001), and hypertension (HR = 1.16, 95% CI: 1.01-1.34, p = 0.04). Dyslipidemia exhibited an inverse result for PD (HR = 0.6, 95% CI: 0.52-0.68, p < 0.001). Conclusions: This population-based study did not identify an association between gout and PD. Age, female sex, stroke, and hypertension were identified as independent risk factors for PD, and dyslipidemia demonstrated an inverse result for PD.
引用
收藏
页数:9
相关论文
共 46 条
[1]   Influence of serum uric acid levels on prognosis and survival in amyotrophic lateral sclerosis: a meta-analysis [J].
Abraham, Alon ;
Drory, Vivian E. .
JOURNAL OF NEUROLOGY, 2014, 261 (06) :1133-1138
[2]   Neurobiology - Cholesterol - Making or breaking the synapse [J].
Barres, BA ;
Smith, SJ .
SCIENCE, 2001, 294 (5545) :1296-1297
[3]   The neurosteroid pregnenolone sulphate increases dopamine release and the dopaminergic response to morphine in the rat nucleus accumbens [J].
Barrot, M ;
Vallée, M ;
Gingras, MA ;
Le Moal, M ;
Mayo, W ;
Piazza, PV .
EUROPEAN JOURNAL OF NEUROSCIENCE, 1999, 11 (10) :3757-3760
[4]   Incidence and prevalence of Parkinson's disease in Buenos Aires City, Argentina [J].
Bauso, D. J. ;
Tartari, J. P. ;
Stefani, C. V. ;
Rojas, J. I. ;
Giunta, D. H. ;
Cristiano, E. .
EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 (08) :1108-1113
[5]   Modifiable risk and protective factors in disease development, progression and clinical subtypes of Parkinson's disease: What do prospective studies suggest? [J].
Belvisi, Daniele ;
Pellicciari, Roberta ;
Fabbrini, Giovanni ;
Tinazzi, Michele ;
Berardelli, Alfredo ;
Defazio, Giovanni .
NEUROBIOLOGY OF DISEASE, 2020, 134
[6]   Incidence of Parkinson disease and parkinsonism in three elderly populations of central Spain [J].
Benito-León, J ;
Bermejo-Pareja, F ;
Morales-González, JM ;
Porta-Etessam, J ;
Trincado, R ;
Vega, S ;
Louis, ED .
NEUROLOGY, 2004, 62 (05) :734-741
[7]   EFNS/MDS-ES recommendations for the diagnosis of Parkinson's disease [J].
Berardelli, A. ;
Wenning, G. K. ;
Antonini, A. ;
Berg, D. ;
Bloem, B. R. ;
Bonifati, V. ;
Brooks, D. ;
Burn, D. J. ;
Colosimo, C. ;
Fanciulli, A. ;
Ferreira, J. ;
Gasser, T. ;
Grandas, F. ;
Kanovsky, P. ;
Kostic, V. ;
Kulisevsky, J. ;
Oertel, W. ;
Poewe, W. ;
Reese, J. -P. ;
Relja, M. ;
Ruzicka, E. ;
Schrag, A. ;
Seppi, K. ;
Taba, P. ;
Vidailhet, M. .
EUROPEAN JOURNAL OF NEUROLOGY, 2013, 20 (01) :16-+
[8]   URIC-ACID IRON-ION COMPLEXES - A NEW ASPECT OF THE ANTIOXIDANT FUNCTIONS OF URIC-ACID [J].
DAVIES, KJA ;
SEVANIAN, A ;
MUAKKASSAHKELLY, SF ;
HOCHSTEIN, P .
BIOCHEMICAL JOURNAL, 1986, 235 (03) :747-754
[9]   Epidemiology of Parkinson's disease [J].
de Lau, Lonneke M. L. ;
Breteler, Monique M. B. .
LANCET NEUROLOGY, 2006, 5 (06) :525-535
[10]   Iron chelation in the treatment of neurodegenerative diseases [J].
Dusek, Petr ;
Schneider, Susanne A. ;
Aaseth, Jan .
JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY, 2016, 38 :81-92